VivoSeq
Cardiovascular

Myocardial Ischemia

34

Pipeline Programs↗

2

Active Trials↗

20

Companies Involved↗

Myocardial Ischemia is a moderately active landscape with 34 programs across 20 companies. The most active players are Iovance Biotherapeutics, Inc., Menarini International Operations Luxembourg SA, Roche. 20 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

0/100

Mech. Concentration

4/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1M

Menarini International Operations Luxembourg SA

1 program

Phase 2Roche logo

Roche

1 program

Phase 2S

Shanghai IxCell Biotechnology Co., LTD

1 program

Phase 2I

Immunex

1 program

Phase 3Bayer logo

Bayer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

31 of 37 classified programs — the dominant modality here.

16%ALL OTHERSProtein / enzyme25%Cell therapy25%Peptide13%Radiopharmaceutical13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed15 · 65%
Unknown status6 · 26%
Recruiting2 · 9%

Clinical Trials

Trial Activity

23 trials

Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
Recruiting·TThe Second Hospital of Anhui Medical University·N/A·NCT06947135·166 enrolled
Magnetocardiography in the Identification of Non-Obstructive Myocardial Ischemia of Patients With Acute Chest Pain
Recruiting·QQilu Hospital of Shandong University·N/A·NCT07657546·3,786 enrolled
Myocardial Ischemia and Transfusion
Completed·RRutgers, The State University of New Jersey·Phase 3·NCT02981407·3,506 enrolled
Effects of Ivabradine on Residual Myocardial Ischemia After PCI
Completed·AAzienda Policlinico Umberto I·Phase 4·NCT03866395·28 enrolled
QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia
Completed·UUniversity of Florida·Phase 4·NCT00150826·78 enrolled
MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)
Completed·—·Phase 2·NCT01449032·60 enrolled
EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Completed·UUniversity of Florida·Phase 4·NCT00187889·70 enrolled
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000472
Myocardial Ischemia and Transfusion Pilot
Completed·RRutgers, The State University of New Jersey·Phase 3·NCT01167582·110 enrolled
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01797484·20 enrolled
Responses of Myocardial Ischemia to Escitalopram Treatment
Completed·—·Phase 4·NCT00574847·127 enrolled
Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
Completed·UUniversity Medical Center Groningen·Phase 2·NCT00524901·10 enrolled
Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass
Completed·—·Phase 4·NCT05598177·64 enrolled
Cardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia
Completed·UUppsala University·Phase 4·NCT00777166·103 enrolled
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
Completed·—·N/A·NCT01342029·142 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)